23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › RECURSION PHARMACEUTICALS, INC. › 2025-2026

RECURSION PHARMACEUTICALS, INC. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and RECURSION PHARMACEUTICALS, INC.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 295Asset managers, any item
  • 1,052Fund votes
  • June 17, 2026Meeting date

Results at a glance

Meeting of June 17, 2026: 4 items on RECURSION PHARMACEUTICALS, INC.’s Form 8-K, filed June 18, 2026: 2 elected · 2 approved.

Dissent

Notable dissent: 2 directors (12.7%, 11.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore RECURSION PHARMACEUTICALS, INC. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by RECURSION PHARMACEUTICALS, INC.

These tallies are RECURSION PHARMACEUTICALS, INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

RECURSION PHARMACEUTICALS, INC. — official shareholder meeting results, meeting held June 17, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Najat Khan, Ph.D. 210,437,751---- 27,907,256126,675,762 88%Elected—
Elect Director: Franziska Michor, Ph.D. 208,124,737---- 30,220,270126,675,762 87%Elected—
2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement 206,171,00830,893,1471,280,852 --126,675,762 87%Approved—
3. Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 361,743,5002,148,7711,128,498 ---- 99.4%Approved—

Source: RECURSION PHARMACEUTICALS, INC., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.

How asset managers voted at the RECURSION PHARMACEUTICALS, INC. 2025-2026 meeting

295 asset managers disclosed a vote on at least one RECURSION PHARMACEUTICALS, INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Najat Khan, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 210,437,751WITHHELD: 27,907,256
Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: Election of Directors: Najat Khan, Ph.D.

RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Elect Director: Najat Khan, Ph.D.”): 210,437,751 for, 27,907,256 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026 (the "Proxy Statement"): Proposal 1: T…”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 54 asset managers below reported 13,524,020 for, 1,139,490 withheld, 15,336 abstained.

FOR
FOR: 13,524,020ABSTAIN: 15,336WITHHOLD: 1,139,490
Largest asset managers voting on “Election of Directors: Najat Khan, Ph.D.” at RECURSION PHARMACEUTICALS, INC., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,358,4420 30For
State Street1,881,4990 02,160For
ARK Venture Fund620,7650 00For
BlackRock594,7140 00For
Lincoln Financial370,7610 091,230Mixed
Fidelity439,1720 00For
Charles Schwab383,8650 00For
Equitable366,5120 00For
FundVantage Trust00 0311,293Withhold
Guggenheim00 0204,222Withhold
American Century00 0132,750Withhold
Bridge Builder Trust87,1000 00For
Global X78,7290 00For
SEI78,3000 00For
Themes ETF Trust00 077,000Withhold
JPMorgan66,2290 00For
DWS00 064,004Withhold
AMERICAN BEACON FUNDS62,6660 00For
AIG/SunAmerica00 057,414Withhold
AuguStar00 044,555Withhold
Calvert00 037,513Withhold
Direxion Shares ETF Trust00 037,311Withhold
ProShares00 035,438Withhold
Venerable Variable Insurance Trust34,5420 00For
Principal00 028,907Withhold

Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).

Elect Director: Franziska Michor, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 208,124,737WITHHELD: 30,220,270
Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: Election of Directors: Franziska Michor, Ph.D.

RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Elect Director: Franziska Michor, Ph.D.”): 208,124,737 for, 30,220,270 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026 (the "Proxy Statement"): Proposal 1: T…”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 54 asset managers below reported 13,227,070 for, 1,436,440 withheld, 15,336 abstained.

FOR
FOR: 13,227,070ABSTAIN: 15,336WITHHOLD: 1,436,440
Largest asset managers voting on “Election of Directors: Franziska Michor, Ph.D.” at RECURSION PHARMACEUTICALS, INC., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,358,4420 30For
State Street1,881,4990 02,160For
ARK Venture Fund620,7650 00For
BlackRock594,7140 00For
Lincoln Financial370,7610 091,230Mixed
Fidelity439,1720 00For
Charles Schwab383,8650 00For
Equitable69,5630 0296,949Mixed
FundVantage Trust00 0311,293Withhold
Guggenheim00 0204,222Withhold
American Century00 0132,750Withhold
Bridge Builder Trust87,1000 00For
Global X78,7290 00For
SEI78,3000 00For
Themes ETF Trust00 077,000Withhold
JPMorgan66,2290 00For
DWS00 064,004Withhold
AMERICAN BEACON FUNDS62,6660 00For
AIG/SunAmerica00 057,414Withhold
AuguStar00 044,555Withhold
Calvert00 037,513Withhold
Direxion Shares ETF Trust00 037,311Withhold
ProShares00 035,438Withhold
Venerable Variable Insurance Trust34,5420 00For
Principal00 028,907Withhold

Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).

Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

87% Approved · of votes cast

FOR 87%
FOR: 206,171,008AGAINST: 30,893,147

Prior year: 98.7% for (June 18, 2025 meeting) ▼ 11.7 pts

Details: description as filed, official tally, votes by 288 asset managers

Description as filed by funds: ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT.

RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement”): 206,171,008 for, 30,893,147 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of RECURSION PHARMACEUTICALS, INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (6 managers, 1,570 for, 13,679,273 against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 55 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT.” at RECURSION PHARMACEUTICALS, INC., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,356,8301,616 00For
State Street1,879,0984,561 00For
ARK Venture Fund620,7650 00For
BlackRock594,7140 00For
Lincoln Financial370,76191,230 00Mixed
Fidelity439,1720 00For
Charles Schwab383,8650 00For
Equitable69,563296,949 00Mixed
FundVantage Trust0311,293 00Against
Guggenheim0204,222 00Against
American Century0132,750 00Against
Investment Managers Series Trust II102,6920 00For
Bridge Builder Trust87,1000 00For
Global X78,7290 00For
SEI78,3000 00For
Themes ETF Trust077,000 00Against
JPMorgan66,2290 00For
DWS064,004 00Against
AMERICAN BEACON FUNDS62,6660 00For
AIG/SunAmerica057,414 00Against
AuguStar00 44,5550Abstain
Calvert037,513 00Against
Direxion Shares ETF Trust037,311 00Against
ProShares035,438 00Against
Venerable Variable Insurance Trust34,5420 00For

Fund voting reports, all 55 managers: 13,306,787 for, 1,431,097 against, 44,555 abstained, 1 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 246 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT.” at RECURSION PHARMACEUTICALS, INC., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BAILLIE GIFFORD & CO LTD20,028,7190 00For
MIC Capital Management UK LLP8,451,7580 00For
Amova Asset Management Co., Ltd.05,384,024 00Against
State Street5,093,92639,340 00For
Vanguard4,316,13418,935 00For
Lingotto Investment Management LLP4,062,7290 00For
BlackRock3,614,59070,780 00For
MARSHALL WACE, LLP3,064,3570 00For
ARK Investment Management LLC3,034,4180 00For
Northern Trust2,035,454132,271 00Mixed
Goldman Sachs1,009,85153,053 00For
STIFEL NICOLAUS & CO INC \MO\0945,102 00Against
Man Group plc843,2850 00For
CAPITAL FUND MANAGEMENT S.A.818,8920 00For
BNP Paribas Asset Management Holding S.A.0762,609 00Against
Vestmark Advisory Solutions, Inc.702,3110 00For
MELLON INVESTMENTS Corp610,1330 00For
T. Rowe Price0546,302 00Against
UBS0533,148 00Against
AllianceBernstein0448,204 00Against
Lazard0389,686 00Against
Charles Schwab386,1320 00For
Allianz0340,440 00Against
Gotham Asset Management, LLC0317,188 00Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC262,4650 00For

Institutional-manager reports, all 246 managers: 61,337,371 for, 12,316,148 against, 4,937 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%
FOR: 361,743,500AGAINST: 2,148,771
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2026.

RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“3. Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026”): 361,743,500 for, 2,148,771 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 was ratified, with the following votes cast:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 14,739,544 for, 44,555 abstained.

FOR
FOR: 14,739,544ABSTAIN: 44,555
Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting ” at RECURSION PHARMACEUTICALS, INC., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,358,4450 00For
State Street1,883,6590 00For
ARK Venture Fund620,7650 00For
BlackRock594,7140 00For
Lincoln Financial461,9910 00For
Fidelity439,1720 00For
Charles Schwab383,8650 00For
Equitable366,5120 00For
FundVantage Trust311,2930 00For
Guggenheim204,2220 00For
American Century132,7500 00For
Investment Managers Series Trust II102,6920 00For
Bridge Builder Trust87,1000 00For
Global X78,7290 00For
SEI78,3000 00For
Themes ETF Trust77,0000 00For
JPMorgan66,2290 00For
DWS64,0040 00For
AMERICAN BEACON FUNDS62,6660 00For
AIG/SunAmerica57,4140 00For
AuguStar00 44,5550Abstain
Calvert37,5130 00For
Direxion Shares ETF Trust37,3110 00For
ProShares35,4380 00For
Venerable Variable Insurance Trust34,5420 00For

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of June 18, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest RECURSION PHARMACEUTICALS, INC. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 530,628,653 shares outstanding at the time of that meeting.

Fund voting reports: top RECURSION PHARMACEUTICALS, INC. shareholders by shares voted on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 1.58%
2State Street 0.35%
3ARK Venture Fund 0.12%
4BlackRock 0.11%
5Lincoln Financial 0.09%
6Fidelity 0.08%
7Charles Schwab 0.07%
8Equitable 0.07%
9FundVantage Trust 0.06%
10Guggenheim 0.04%
Institutional-manager reports: top RECURSION PHARMACEUTICALS, INC. shareholders by shares voted on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT.”, 2025-2026
#Asset manager % of shares outstanding
1BAILLIE GIFFORD & CO LTD 3.77%
2MIC Capital Management UK LLP 1.59%
3Amova Asset Management Co., Ltd. 1.01%
4State Street 0.97%
5Vanguard 0.82%
6Lingotto Investment Management LLP 0.77%
7BlackRock 0.69%
8MARSHALL WACE, LLP 0.58%
9ARK Investment Management LLC 0.57%
10Northern Trust 0.41%

Reported RECURSION PHARMACEUTICALS, INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

RECURSION PHARMACEUTICALS, INC. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group47,187,759 8.89%Form 13F, quarter ended March 31, 2026
BlackRock43,192,306 8.14%Form 13F, quarter ended March 31, 2026
ARK Investment Management LLC37,316,856 7.03%Schedule 13G, filed February 3, 2026
Vanguard Portfolio Management31,369,274 5.91%Schedule 13G, filed July 31, 2026
State Street28,490,638 5.37%Form 13F, quarter ended March 31, 2026
BAILLIE GIFFORD & CO23,774,972 4.48%Schedule 13G, filed February 5, 2026
Zachary Bogue13,628,602 2.57%Proxy statement (DEF 14A), table as of April 21, 2026
Blake Borgeson6,374,101 1.20%Proxy statement (DEF 14A), table as of April 21, 2026
Goldman Sachs6,065,661 1.14%Form 13F, quarter ended March 31, 2026
Morgan Stanley5,657,578 1.07%Form 13F, quarter ended March 31, 2026

Percentages above are of 530,628,653 shares outstanding, as reported by RECURSION PHARMACEUTICALS, INC. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At RECURSION PHARMACEUTICALS, INC.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 295 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,052 separate fund positions. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT. — RECURSION PHARMACEUTICALS, INC.'s filing reports the proposal as approved, with 87% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RECURSION PHARMACEUTICALS, INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RECURSION PHARMACEUTICALS, INC.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

RECURSION PHARMACEUTICALS, INC. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “RECURSION PHARMACEUTICALS (RXRX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/recursion-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.